Drug intelligence / Profile preview

SEDALAM

Development stage: Unknown
Lead developer: Franz Köhler Chemie
Modality: Small Molecules
Administration: Intravenous

Overview

SEDALAM is an intravenous formulation of lormetazepam, a benzodiazepine developed and marketed by Dr. Franz Köhler Chemie GmbH. It is provided as a 2 mg/10 ml injection solution. Lormetazepam acts as a positive allosteric modulator of the Gamma-aminobutyric acid type A (GABA-A) receptor in the central nervous system, enhancing the inhibitory effects of gamma-aminobutyric acid. SEDALAM is primarily indicated for the symptomatic treatment of acute tension, agitation, and anxiety states during surgical and diagnostic procedures, as well as for sedation in intensive care medicine and anesthesia induction. Its profile allows for precise control of sedation depth, typically targeting a Richmond Agitation-Sedation Scale (RASS) of 0 to -1, with a low side effect profile.

Brand names: SEDALAM
Other names: lormetazepam injection

Targets

GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on SEDALAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEDALAM.

Explore the full profile